CMS expands Medicare coverage for Personalis's NeXT Personal test to monitor neoadjuvant therapy in breast cancer

Personalis, Inc.

New coverage applies to monitoring treatment response to neoadjuvant therapy in Stage II-III TNBC or HER2+ breast cancer patients.
Expansion effective May 19, 2026, under CMS Molecular Diagnostics Program.
NeXT Personal is an ultrasensitive liquid biopsy test; this indication broadens addressable patient population.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.